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Inhibition of microRNA-21 via  
locked nucleic acid-anti-miR  
suppressed metastatic features  
of colorectal cancer cells through 
modulation of programmed cell death 4
Reza Nedaeinia1,2, Mohammadreza Sharifi3, Amir Avan4, 
Mohammad Kazemi3, Abdolreza Nabinejad5, Gordon A Ferns6, 
Majid Ghayour-Mobarhan4,7 and Rasoul Salehi3,8,9
Abstract
Colorectal cancer is among the most lethal of malignancies, due to its propensity to metastatic spread and multifactorial-
chemoresistance. The latter property supports the need to identify novel therapeutic approaches for the treatment of 
colorectal cancer. MicroRNAs are endogenous non-coding small RNA molecules that function as post-transcriptional 
regulators of gene expression. Recently, programmed cell death 4 has been identified as a protein that increases 
during apoptosis. This gene is among the potential targets of miR-21 (OncomiR). Locked nucleic acid–modified 
oligonucleotides have recently emerged as a potential therapeutic option for targeting microRNAs. The aim of this 
study was to explore the functional role of locked nucleic acid-anti-miR-21 in the LS174T cell line in vitro and in vivo 
models. LS174T cells were treated with locked nucleic acid-anti-miR-21 for 24, 48, and 72 h in vitro. The expression 
of miR-21 and PDCD4 at messenger RNA (mRNA) level was evaluated by quantitative real-time polymerase chain 
reaction, while the protein level of PDCD4 was determined by Western blotting. Cell migratory behavior and the 
cluster-forming ability of cells were assessed before and after therapy. The disseminated tumor cells were assessed 
in the chick chorioallantoic membrane model by Alu quantitative polymerase chain reaction. Locked nucleic acid-anti-
miR-21 was transfected successfully into the LS174T cells and inhibited the expression of miR-21. Locked nucleic 
acid-anti-miR-21 inhibited the migration and the number of cells forming clusters. Moreover, we found that locked 
nucleic acid-anti-miR-21 transfection was associated with a significant reduction in metastatic properties as assessed 
by the in ovo model. Our findings demonstrated the novel therapeutic potential of locked nucleic acid-anti-miR-21 in 
colon adenocarcinoma with high miR-21 expression.
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Introduction
Colorectal cancer (CRC) is the third leading cause of can-
cer-related death.1 The America Cancer Society has pre-
dicted that there would be 95,270 cases of colon cancer 
and 39,220 cases of rectal cancer in 2016 in the United 
States. Moreover, it is expected that more than 49,190 
deaths from CRC will occur in 2016 in the United States.2 
Despite extensive clinical and preclinical developments, 
the prognosis of CRC is still extremely poor, because of its 
aggressive properties and its intrinsic resistance to most 
chemotherapeutic agents.3 Our data provide a proof of 
principle for developing a new therapeutic approach and 
identifying the molecular mechanisms underlying the drug 
resistance in CRC.
Recently, programmed cell death 4 (PDCD4) has been 
identified as a tumor suppressor gene and is being sug-
gested as a potential therapeutic target. This gene is among 
the potential targets of microRNA-21 (miR-21), although 
the molecular mechanism is still obscure.4 It has been 
shown that PDCD4 can interact with several translational 
factors, including eukaryotic translation initiation factor-
4G (eIF4G) and eukaryotic translation initiation factor-
4A (eIF4A), and could suppress translation of mRNA.5,6 
High levels of PDCD4 may be associated with reduced 
levels of dUTPase and might contribute to the tumor sup-
pressor function of PDCD4 in Bon-1 cells.4 The regula-
tory role of PDCD4 is mediated via P21,7 Cdk4, ornithine 
decarboxylase,8 carbonic anhydrase II,9 JNK/c-Jun/
AP-1,5,10 and tissue inhibitor of metalloproteinase 2 
(TIMP-2).11 The downregulation of PDCD4 in lung and 
colorectal cancers has been found to be associated with a 
poor prognosis.12,13
Chen et al.14 evaluated the prognostic value of PDCD4 
using two molecular profiling techniques complementary 
DNA (cDNA) and tissue microarray analysis in 124 
patients with primary lung carcinomas. They identified 
PDCD4 as a potential prognostic factor for the prediction 
of disease outcome. Another study has shown that PDCD4 
suppresses tumor phenotype via inhibiting c-Jun and c-Fos 
activation in transformed (Tx) mouse epidermal JB6, 
RT101, cells.15 It has also been reported that enforced 
expression of PDCD4 inhibited tumorigenesis and malig-
nant progression in K14-PDCD4 transgenic mice.8 
However, it has also been shown that miR-21 can act as 
cooperative repressors of PDCD4 in pancreatic ductal 
adenocarcinoma.16
MiR-21 is one of the most prominent microRNAs (miR-
NAs) implicated in the development and progression of dif-
ferent cancers, which has been shown to be involved in 
tumor progression,17 proliferation18 and with an anti-apop-
totic effect19 as well as its association with tumor resistance 
to chemotherapy.20,21 There is a growing body of evidence 
showing miR-21 aberrant expression in CRC,19,20,22 sug-
gesting its value as a prognostic biomarker.23,24
Locked nucleic acid (LNA)-anti-miRs are a new class 
of modified oligonucleotides25 that bind to miRNA and 
can modulate miRNA expression. They are very similar to 
RNAs, methylene bridge connecting the 2′-oxygen atom 
and the 4′-carbon atom (2′-O 4′-C methylene) in the ribose 
ring. This bridge forms a bi-cyclic structure that locks the 
ribose conformation and is integral to the high stability and 
low toxicity in biological systems and affinity of the LNA 
to its complementary RNA sequences.26 LNA oligonucleo-
tides are stable in the modulation of RNAs, have a good 
aqueous solubility, and do not cause an immune response, 
suggesting their value for antisense-based gene silencing 
in gene therapy.23,27 Therefore, in the current study, we 
explored the anti-tumor activity of LNA-anti-miR-21 in 
colon adenocarcinoma cells and the modulation of PDCD4 
expression, through the analysis of cell migration and met-
astatic features of LS174T cells. This cell line is mucin-
producing colorectal cell line mimicking the condition 
usually happens in younger patients with interference of 
high amounts of mucin in treatment effectiveness. The fact 
that mucin production hampers effective therapy remained 
obscure in previous works.
Materials and methods
Cell culture
The human colorectal adenocarcinoma cell line LS174T 
was obtained from the National Cell Bank of Iran (Pasteur 
Institute, Tehran, Iran) and was maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco, Grand Island, 
NY, USA) with 4.5 g/L glucose, supplemented with 10% 
fetal bovine serum (FBS; Bio-IDEA, Tehran, Iran), 2-mM 
L-glutamine, 100 IU/mL penicillin, and 100 µg/mL strepto-
mycin (Bio-IDEA). The cells were cultured to their expo-
nential growth phase. LS174T cells were harvested using 
trypsin-EDTA and incubated at 37°C with 5% CO2.
Cell transfection with LNA-anti-miR-21
Nucleotide sequences of miR-21 and related scientific 
data were obtained from a reputable site of www.mirbase.
org. Human miR-21 has the accession number 
MIMAT0000076, with a sequence of nucleotides in the 
form of 5'- UAGCUUAUCAGACUGAUGUUGA-3'. 
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The inhibition interaction between miRNAs on mRNA 
PDCD4 was obtained by using EMBL-EBI (MicroCosm 
Targets version 5), target scan program, and miRTarBase 
database. The LS174T cells were transfected with LNA-
anti-miR-21, miRCURY LNA inhibitor (anti-miR), or 
scrambled LNA (Exiqon, Copenhagen, Denmark) using 
the X-tremeGENE siRNA Transfection Reagent Kit™ 
(Roche, Mannheim, Germany) according to the manufac-
turer’s instructions. 5′ end of both nucleotides was marked 
with 6-carboxyfluorescein (6-FAM). Sequences of LNA-
anti-miR-21 and scrambled LNA were as follows: 5′-
3′/56-FAM/ACA TCA GTC TGA TAA GCT and 
5′-3′/56-FAM/GTG TAA CAC GTC TAT ACG CCC A. 
The sequence of negative control was analyzed using 
BLAST search to exclude potential hits in the human tran-
scriptome. Both oligonucleotides were purified by high-
pressure liquid chromatography (HPLC). In brief, for cell 
transfection, 2 × 105 LS174T cells were cultured in each 
six-well culture plates (SPL Life Sciences, Pocheon, 
Korea), and plates were kept in a cell culture incubator in 
37°C and 5% CO2 for 24 h. For standard transfection, the 
culture medium was completely removed from each well 
and the cells were washed with phosphate-buffered saline 
(PBS; 1×) and serum-free medium for three times to 
decrease mucus layer on the cells, and subsequently, 
1.8 mL of fresh medium containing 2.7% serum without 
antibiotics was added to each well containing cells. 2-µL 
of scrambled LNA or LNA-anti-miR (50 pmol/µL) was 
added separately with 5-µL X-tremeGENE siRNA trans-
fection reagent in 200 µL Opti-MEMI (Gibco), followed 
by incubation in a dark room for 20 min at room tempera-
ture. The resulting complex was added to each well and 
slowly swirled while adding the complex to spread 
entirely in all parts of the plate. The plate was incubated 
for 10 h. Then, 200-µL FBS was added to each well, and 
the cells were incubated for 24, 48, and 72 h. The reverse 
transfection method was used for evaluation of cluster 
formation assay. In this method, LS174T cells were trans-
fected in a state of suspension. Briefly, 4 × 105 cells were 
added to each well of 6-well low attachment plates (SPL 
Life Sciences), and subsequently, 1.8-mL DMEM with 
2.7% FBS without antibiotics was added to each well. 
Transfection complexes of 200 µL were added to the cells. 
After 10 h, 200-µL 10% FBS was added to each well to 
maintain maximum viability.
Transfection efficiency was examined by fluorescence 
microscope (Olympus, Tokyo, Japan) and then analyzed 
by FACSCalibur flow cytometer (Becton-Dickinson 
Immunocytometry Systems, Franklin Lakes, NJ, USA).
Quantitative real-time polymerase chain 
reaction
Reverse transcriptase real-time polymerase chain reaction 
qRT-PCR was used to evaluate the efficiency of miR-21 
inhibition by LNA-anti-miR-21 after 24, 48, and 72 h of 
transfection. Total RNA was extracted from LS174T cells 
after 24, 48, and 72 h of transfection by the miRCURY 
RNA Isolation Kit™ (Exiqon) according to the manufac-
turer’s instructions. The concentration of RNA was meas-
ured using a NanoDrop Epoch (BioTek Instruments, 
Winooski, VT, USA). cDNA was synthesized by the 
Universal cDNA Synthesis Kit (Exiqon). Relative levels of 
miRNA were examined using the SYBR Green Master 
Mix Kit™ (Exiqon) with specific primers which hsa-miR-
21-5p (Product No. 204230; Exiqon) and hsa-let-7a-5p 
(Product No. 205727; Exiqon)28 as an internal control 
(Exiqon) to normalize quantitative real-time PCR (qRT-
PCR). The relative miR-21 and let-7a expression were cal-
culated using the ∆∆CT method. Moreover, for evaluation 
of PDCD4 gene expression, total RNA was extracted as 
described above and cDNA was synthesized by the 
Fermentas kit (Fermentas Life Science, Vilnius, Lithuania) 
according to the manufacturer’s instructions. qRT-PCR 
was performed using the SYBR® Green Master Mix Kit 
(Exiqon) according to the manufacturer’s instructions. The 
primers’ sequences for PDCD4 were as follows: forward, 
5′-AAAGGGAAGGTTGCTGGATAGG-3′; reverse, 5′- 
CACAGTTCTCCTGGTCATCATCA-3′. GAPDH was 
used as the internal control gene (forward, 5′-AGTCCA 
CTGGCGTCTTCAC-3′; reverse, 5′-AGGCATTGCTGAT 
GATCTTGAG-3′). The relative PDCD4 and GAPDH 
expression were calculated using the ∆∆CT method. The 
StepOnePlus™ (Applied Biosystems, Foster City, CA, 
USA) instrument was used for real-time PCR experiments 
under the following conditions: polymerase activation at 
95°C for 10 min followed by 40 cycles at 95°C for 10 s and 
60°C for 1 min.
Western blot analysis
The level of protein expression of PDCD4 was determined 
after 24, 48, and 72 h following transfection in the three 
groups of cells (transfected by LNA-anti-miR, transfected 
by scrambled LNA, and untreated cells) by using Western 
blot analysis. Total protein was extracted using RIPA 
(Radioimmunoprecipitation) lysis buffer (Santa Cruz 
Biotechnology, Santa Cruz, California, USA) containing 
RIPA, phenyl methyl sulfoxide (PMSF), sodium orthova-
nadate solution, and protease inhibitor cocktail solution. 
Protein concentrations were determined by the Quick 
Start™ Bradford Protein Assay Kit™ (Bio-Rad, Hercules, 
CA, USA). Electrophoresis was performed in discontinu-
ous system of Laemmli29 at 15°C in a vertical slab filled 
with electrophoresis buffer (25-Mm Tris, 192-mM gly-
cine, and 0.1% sodium dodecyl sulfate (SDS), pH 8.3). 
Equal aliquots of solubilized total protein sample (100 µg 
per lane) were resolved on 12% polyacrylamide gel elec-
trophoresis with 6% stacking gel. A prestained protein 
marker (9–170 kDa; CinnaGen, Tehran, Iran) was used to 
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estimate the molecular weight of proteins resolved by elec-
trophoresis. Electrophoresis was applied with 20 mA per 
gel until the bromophenol blue had reached the separation 
gel. The current was then increased to 30 mA until the dye 
had migrated through the separation gel. Afterward, the 
gels were removed and the proteins were transferred onto 
the nitrocellulose membrane (Amersham, Piscataway, NJ, 
USA). The membranes were then blocked with buffer con-
taining 5% skimmed milk (Sigma, St. louis, USA) and 
0.05% Tween-20 (polyoxyethylene-20 sorbitan monolau-
rate)(Merck, Darmstadt, Germany) at 4°C. Mouse mono-
clonal antibody anti-human PDCD4 (Santa Cruz 
Biotechnology) and mouse monoclonal antibody anti-
human β-actin (Santa Cruz Biotechnology) were used at 
1:200 dilution. The secondary antibody, horseradish perox-
idase–conjugated goat anti-mouse IgG (Santa Cruz 
Biotechnology) was used at 1: 2000 dilutions. The position 
of the protein was visualized using diaminobenzidine 
(DAB; Sigma-Aldrich Company Ltd, Gillingham, UK) 
reagent. Results of densitometric analyses of Western blots 
were measured by ImageJ software ver. 1.42q (National 
Institute of Health, Bethesda, MD, USA). The β-actin was 
utilized as an internal control for normalization.
Scratch cell migration assay
For the migration assay, 2 × 105 cells/well were seeded into 
six-well plates (SPL Life Sciences) and grown to 90% con-
fluence at 37°C with 5% CO2. Then, culture medium on 
the cells was removed; cells were washed with PBS solu-
tion and exposed overnight in medium containing 0.5% 
serum. Afterward, a direct scratch on the bottom plate 
using three vertical scratches was created by using a steri-
lized glass rod with a sharp tip; the cells were gently 
washed with PBS to remove non-adherent cells separated 
from the plate’s bottom area and replaced with 1.8 mL of 
fresh medium containing 2.7% FBS solution. After 24, 48, 
and 72 h following transfection in three groups of cells 
(transfected by LNA-anti-miR, transfected by scrambled 
LNA, and untreated cells), cell migration was evaluated by 
counting cells at 24, 48, and 72 h post transfection that 
migrated from the scratch edge. The average numbers of 
migratory cells in three random fields were counted at 
200× magnification using an inverted light microscope 
(Nikon TS100, Tokyo, Japan).
Cluster-formation assay
For the cluster formation assay, cell suspensions were 
resuspended in DMEM supplemented with 2.7% FBS. 10h 
after reverse transfection, 2 × 104 cells were seeded into 
24-well ultra-low attachment plates (Corning, Corning, 
NY, USA) and incubated at 37°C with 5% CO2 for 48 h. 
Suspensions of cell clusters were transferred into six-well 
plates (SPL Life Sciences). After 24-h incubation at 37°C 
with 5% CO2, cell clusters attached to the bottom of the 
plate for evaluation of biomass. The clusters were stained 
with cell stain solution (Cell Biolabs, San Diego, CA, USA) 
for 10 min and then washed with PBS. The average num-
bers of cells forming the cluster in three random fields were 
counted at 200× magnification using an inverted light 
microscope (Nikon TS100) in the three groups (transfected 
with LNA-anti-miR, scrambled LNA, and untreated cells).
In ovo experiments
To assess spontaneous metastasis, fertilized chicken eggs 
were randomly allocated to one of four groups: healthy 
chick embryos, scrambled LNA, LNA-anti-miR, and con-
trol (untreated cells). Fertilized chicken eggs were incubated 
in a rotating incubator at 38°C and 65% humidity for 
10 days. Afterward, the air sac in the blunt end was deter-
mined using light source to candle the eggs. The chorioal-
lantoic vein was detected and marked; 1-cm by 0.5-cm 
rectangle away from the area of capillary network connec-
tions was drawn with a pencil on the egg shell. Then, the 
area including blunt end and around the square was then 
cleaned using an iodine swab. A hole was made using a ster-
ile pin in air sac and central part of the rectangle. Following 
suction made by the pump in the air sac, the new air pocket 
was formed under the drawn rectangle hole showing that 
chorioallantoic membrane (CAM) successfully separated 
from the egg shell. After CAM coming down, a small win-
dow above the rectangle, drawn on the egg shell, was 
removed with a sterile forceps. CAM was abraded using a 
cotton swab. A sterile plastic ring was placed on CAM area. 
All procedures were performed in accordance with the ethi-
cal standards of the local ethics committee of Mashhad 
University of Medical Sciences (permit number: 921797).
Chicken model for metastasis quantification
To study the metastatic features of tumor cells, burden in 
the livers of chicken embryo was determined by real-time 
quantitative PCR (qPCR) to detect human Alu repeats. Alu 
sequences are found in 500,000–1,000,000 copies in the 
haploid genome. They make an excellent target or marker 
for human DNA. After 48-h transfection, 105 cells were 
injected into an approximately 0.8-cm plastic ring placed 
on the 10-day-old chick CAM. After 8 days, the eggs were 
placed on ice for 3 h to anesthetize and euthanize. To assess 
metastasis, the livers were harvested and genomic DNA 
was extracted using the DNA Isolation Kit (Genet Bio, 
Cheonan, Korea). DNA concentration and purity were 
measured spectrophotometrically at an optical density 
(OD) of 260 to 280 nm with NanoDrop Epoch (BioTek). 
The concentration of genomic DNA extracted was regu-
lated to 50 ng/µL. Genomic DNA was diluted 1:10 in 
nuclease-free water before using it in the subsequent PCR 
reaction for amplification. 1-µL diluted genomic DNA was 
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amplified in a total volume of 10-µL reaction, containing 
1× RealQ Plus Master Mix Green (Ampliqon, Odense, 
Denmark), dH2O, and 200 nmol/L of human Alu primers 
(Alu-F 5′-ACGCCTGTAATCCCAGCACTT-3′ and Alu-R 
5′-TCGCCCAGGCTGGAGTGCA-3′) and chick glyceral-
dehyde-3-phosphate dehydrogenase (chGAPDH) specific 
primers (chGAPDH-F 5′-GAGGAAAGGTCGCCTGG 
TGGATCG-3′and chGAPDH-R 5′-GGTGAGGAC 
AAGCAGTGAGGAACG-3′) as endogenous controls. 
Metastasis was assessed using an ABI StepOnePlus™ 
instrument under the following conditions for Alu 
sequences: polymerase activation at 95°C for 15 min fol-
lowed by 30 cycles at 95°C for 30 s, 63°C for 30 s, and 
72°C for 30 s. Quantitative analysis by the ∆∆CT method 
for comparisons between groups was performed. Each 
assay included a negative control (no template controls, 
NTC), genomic DNA extracted from the liver of healthy 
chick embryos to determine the threshold between LS174T 
cells invaded and non-invaded cells.
Data analysis
The experiments were carried out in triplicate and repeated 
at least twice. Data were expressed as mean values ± stand-
ard deviation (SD) and analyzed by two-way analysis of 
variance (ANOVA) with Fisher’s test followed by Scheffé’s 
multiple comparisons test and compare means test-Dun-
nett. Data were analyzed using SPSS version 22 statistical 
software (IBM, Chicago, IL, USA). Statistical significance 
was set at **p < 0.01.
Results
LNA-anti-miR-21 reduced the expression of 
miR-21
We aimed to transfect the LS174T cells with FAM-
labeled scrambled oligonucleotides (scrambled LNA 
group) to evaluate the transfection efficiency. Based on 
primary optimization experiments, different concentra-
tions of the scrambled LNA were added to the cells and 
the transfection efficacy was assessed by fluorescence 
microscopy and flow cytometry. The best results were 
obtained at a concentration of 50 pmol of scrambled LNA 
and 5-µL X-tremeGENE siRNA transfection reagent. We 
found that the transfection efficacy was >85% (Figure 
1(a) and (b)).
In order to see whether the target was inhibited, the 
expression level of miR-21 was evaluated by qRT-PCR after 
transfection for the 24, 48, and 72 h. This analysis revealed 
Figure 1. Transfection of LS174T cells. (a) LS174T cells were transfected with scrambled LNA 6-carboxyfluorescein (6-FAM)-
labeled, as detected by fluorescent microscopy (×200); scale bars: 50µm; (b) fluorescence-activated cell sorting (FACS) analysis; (c) 
miR-21 expression after 24-, 48-, and 72-h transfection by qRT-PCR; data were mean ± 2SE of three independent  experiments in 
the graph (**p < 0.01).
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the downregulation of miR-21 in the LNA-anti-miR group. 
At all three time points, the expression of miR-21 was sig-
nificantly lower in the LNA-anti-miR group compared with 
scrambled LNA and untreated groups (**p < 0.01; control: 
1 ± 0.0, scrambled LNA: 1.01 ± 0.088, and LNA-anti-miR: 
0.018 ± 0.013; Figure 1(c)).
LNA-anti-miR-21 modulated the PDCD4 
expression in LS174T cells
The expression pattern of PDCD4 was determined in cells 
before and after transfection with LNA-anti-miR-21 com-
pared with scrambled LNA and untreated groups at mRNA 
and protein levels. We observed that the level of mRNA 
PDCD4 was significantly increased at 48 h after transfec-
tion with LNA-anti-miR-21, although this effect was more 
pronounced after 72 h (Figure 2(a)). Notably, when 
LS174T cells were transfected with LNA-anti-miR, a sig-
nificant increase in PDCD4 mRNA expression levels was 
apparent compared with the control and scrambled LNA 
groups (**p < 0.01).
There was a statistically significant inverse correlation 
(r = −0.502; **p < 0.01) between miR-21 inhibition and 
PDCD4 mRNA, which may be due to translational repres-
sion instead of mRNA degradation by miR-21 because an 
r indicates a weak correlation between the variables. We 
also evaluated the protein expression of PDCD4 (Figure 
2(b)). A strong inverse correlation was found between 
miR-21 inhibition and PDCD4 protein (r = −0.853). The 
regression equation was used to evaluate the molecular 
weight with respect to the distance from the surface of 
membrane (Figure 2(c)). At all three time points, these 
data showed that the highest amount of PDCD4 protein 
was associated to LNA-anti-miR-21-transfected cells 
(control: 0.16 ± 0.25, scrambled LNA: 0.14 ± 0.21, and 
LNA-anti-miR: 2.85 ± 1.37), and this effect was greater 
after 48 h.
After 24 h in the LNA-anti-miR-transfected cells, the 
expression level of PDCD4 protein was increased, but in 
the untreated cells and cells transfected with scrambled 
LNA, PDCD4 protein was not detected. At 24 h, this 
increasing pattern of PDCD4 protein was continued at 48 h 
and decreased at 72 h after transfection, but this reduction 
was not less than that of 24 h after transfection (Figure 
2(b)). In untreated and transfected cells treated with scram-
bled LNA, a very low level of PDCD4 protein was detected 
after 48 and 72 h transfection that may be because of high 
expression of miR-21 in the cells that leads to significant 
translational repression instead of mRNA degradation 
(Figure 2(d)).
Figure 2. PDCD4 expression. (a) The mRNA PDCD4 level 24, 48, and 72 h after transfection was analyzed by qRT-PCR. The 
expression was normalized to GAPDH. Mean ± 2SE of three independent experiments in the graph (**p < 0.01). (b) Protein 
expression of PDCD4 after 24-, 48-, and 72-h transfection as detected by Western blot analysis. The expression was normalized to 
beta-actin protein. (c) The regression curve was created with the distance from surface of the membrane and logarithmic of the 
molecular weight. (d) Density ratio of PDCD4/β-actin by Western blotting performed 24, 48, and 72 h after transfection; bar diagram, 
mean ± 2SE of three independent experiments in the graph (**p < 0.01).
L: LNA-anti-miR; S: scrambled LNA; C: untreated cells (control).
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LNA-anti-miR-21 reduced cell migration
A cell scratch assay was performed to estimate the 
migratory behaviors of the cells after 24-, 48-, and 72-h 
transfection. This analysis showed that LNA-anti-
miR-21 reduced the migratory properties of LS174T 
cells compared with scrambled LNA and untreated cells 
(Figure 3(a)). In addition, the average numbers of cells 
moved across the scraped edge were counted at 24, 48, 
and 72 h post transfection. The average number of 
LS174T cells transfected with LNA-anti-miR-21 that 
migrated for all three time points was 47.44 ± 14.82 cells 
per site. Notably, this average number was significantly 
lower than that for the scrambled LNA (97.77 ± 36.97 
cells per site) and untreated (98.78 ± 38.87 cells per site) 
cells (Figure 3(b)).
LNA-anti-miR-21 decreased cluster-forming 
ability of LS174T cells
We investigated the effect of LNA-anti-miR-21 on clus-
ter-forming ability of LS174T cells. The average number 
of cells forming the cluster was lower in the LS174T cells 
transfected by LNA-anti-miR-21 after 48-h transfection, 
compared with scrambled LNA and untreated cells. In 
particular, the average number of cells forming the cluster 
in transfected cells with LNA-anti-miR-21 was 
20.67 ± 3.21, compared with 51.33 ± 1.53 cells per site for 
scrambled LNA and 50.0 ± 3.0 cells per site for untreated 
cells (Figure 4).
Inhibition of miR-21 reduced liver metastasis
LS174T cells were successfully grafted onto the CAM, 
outlined in Figure 5(a), to investigate the functional sig-
nificance of metastasis in vivo assay. LS174T cells grafted 
CAM model were treated on day 10 with LNA-anti-
miR-21, scrambled LNA, and untreated cells, exposed till 
day 18. After incubation, a primary tumor as the primary 
CAM tumor developed, allowing access to the chick vas-
culature for metastasis to more distant chick tissues. Then, 
livers were harvested and analyzed for metastases (Figure 
5(b)). OD260/OD280 ratios of 1.4–1.8 were accepted to be 
adequate for qPCR for human Alu repeat sequences in 
DNA. The number of tumor cells in the liver was deter-
mined by comparison with a standard curve in which we 
plotted the qPCR signal for Alu repeats against known 
numbers of LS174T cells (Figure 6(a)). Interestingly, we 
observed no metastasis in embryos treated with LNA-anti-
miR-21 (Figure 6(b)). Moreover, the average number of 
metastases was higher in the control group 
(2024.67 ± 1271.22 cells/sample) or scrambled LNA group 
(1490.33 ± 571.24 cells/sample) compared with the 
embryos treated with LNA-anti-miR-21 groups 
(0.05 ± 0.032 cells/sample; Figure 6(c)). Human genomic 
DNA was higher in the control group (0.41 ± 0.3 cells/sam-
ple) or scrambled LNA group (0.3 ± 0.13 cells/sample) 
compared with the embryos treated with LNA-anti-miR-21 
groups (0.00 ± 0.00001 cells/sample; Figure 6(d)). 
However, cells treated with scrambled LNA or untreated 
cells had a significant higher rate of metastasis to liver.
Figure 3. LNA-anti-miR-21 decreased cell migration. (a) Cell migration after 0, 24, 48, and 72 h in three groups: control, scrambled 
LNA, and LNA-anti-miR-transfected cells (magnification: ×200). (b) Different migration abilities of LS174T cells transfected with 
LNA-anti-miR compared with scrambled LNA–transfected cells and control groups in all three time points (**p < 0.01).
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Discussion
To the best of our knowledge, this is the first study evaluat-
ing the inhibitory effect of LNA-anti-miR-21 and explor-
ing its molecular mechanisms in vitro and in vivo, in the 
chick CAM model derived from human colorectal adeno-
carcinoma LS174T cells. Our results suggest that miR-21 
expression could be of relevance to the critical biological 
behavior of colorectal neoplasia. We demonstrated that 
inhibition of miR-21 using novel LNA-anti-miR-21 sup-
pressed its expression in human colorectal adenocarci-
noma LS174T cells and reduced cell migration and liver 
metastasis in the CAM model, most likely through modu-
lation of PDCD4.
There is mounting evidence showing the important role 
of miR-21 in different types of cancer, including 
CRC,17,18,25,26,30–33 which has been suggested to be associ-
ated with poor prognosis and chemoresistance of CRC,34,35 
indicating its value as a potential therapeutic target. 
Furthermore, there appears to be an inverse correlation 
between miR-21 expression and PDCD4 expression15,36,37 
which is in agreement with our data. It has also been docu-
mented that reduced expression of this tumor suppressor 
gene in CRCs is associated with poor prognosis.13,15 In 
particular, Fassan et al.36 evaluated PDCD4 expression in 
300 polypoid lesions of the colon mucosa (50 hyperplastic 
polyps, 50 serrated adenomas, 50 tubular adenomas with 
low-grade intraepithelial neoplasia, 50 tubular adenomas 
with high-grade intraepithelial neoplasia), 50 colon adeno-
carcinomas, and in 50 biopsy samples obtained from 
patients with irritable bowel syndrome as normal controls. 
They showed that miR-21 expression was upregulated in 
pre-neoplastic/neoplastic samples, consistent with PDCD4 
downregulation. Moreover, it has been reported that 
PDCD4 could affect on tumor progression, malignant 
transformation, tumorigenesis,8,15 and apoptosis.38 Wei 
et al.39 investigated the role and mechanism of miR-21 in 
promoting the 5-fluorouracil (5-FU) resistance of pancre-
atic cancer cells in 5-FU resistance cell line 
PATU8988/5-FU. They found that miR-21 regulated 5-FU 
drug resistance PATU8988 and PANC-1 cells via decreas-
ing the expression of PTEN and PDCD4. In turn, enforced 
Figure 4. Transfection of the cells with LNA-anti-miR-21 decreased cluster-forming ability of LS174T cells. Different number of 
counted cells in each cluster transfected with LNA-anti-miR and scrambled LNA compared with control. In cells transfected with 
LNA-anti-miR, the cluster was significantly smaller compared with the other groups (**p < 0.01).
Nedaeinia et al. 9
expression of PDCD4 attenuated the effects of miR-21 in 
5-FU resistance cell line PATU8988/5-FU. Shi and col-
leagues40 found that exosomal levels of miR-21 from cer-
ebrospinal fluids were related with poor prognosis and 
tumor recurrence of glioma patients, whose expression 
was inversely correlated with PDCD4 expression. A simi-
lar study also showed that the downregulation of PDCD4 
was correlated with aromatase inhibitor resistance and 
poor prognosis in estrogen receptor–positive breast cancer 
and forced overexpression of PDCD4 resensitized aro-
matase-resistant cells to aromatase inhibitors or hormone 
deprivation.41 Zhang et al.42 have reported that modulation 
of miR-21 could affect on PDCD4 in hepatocellular 
carcinoma.
These observations provide a proof of principle for the 
modulation of PDCD4 expression via targeting miR-21 in 
CRC as a novel therapeutic option. Therefore, in this study, 
we investigated the inhibitory effects of LNA-anti-miR-21 
in LS174T cells as a possible treatment for CRC. The 
LS174T cell line is able to produce large amounts of mucin 
and inhibit effective transfection.43,44 At the optimized 
level, we found that transfection efficiency was more than 
85%. This amount of transfection is considered to be 
important because one of the key challenges in the 
improvement of effective miRNA-based therapy is the 
delivery of stable and efficient agents into target cells.45 
Although the role of mucin in the behavior of colon cancer 
cells is not clear, other reports have suggested that muci-
nous adenocarcinoma is associated with a poorer out-
come.43 In addition, mucinous carcinoma has a higher 
incidence in the proximal colon and among younger 
patients than non-mucinous adenocarcinoma.43 Our results 
showed that the expression of miR-21 was high, while the 
level of PDCD4 protein was lower in LS174T cells before 
transfection with LNA-anti-miR-21. However, we found 
that PDCD4 protein was markedly enhanced after trans-
fection with LNA-anti-miR-21.
According to this study, miR-21 has a negative regula-
tory effect on PDCD4 and it has anti-apoptotic effects.38 
LNA-anti-miR-21-transfected cells significantly 
increased PDCD4 protein levels, but it almost caused 
weak alternations in PDCD4 mRNA levels. These find-
ings showed that miR-21 inhibits PDCD4 protein pro-
duction. It further suggests that miR-21 regulates PDCD4 
at the level of translational repression, instead of mRNA 
degradation. This finding strongly suggests that a high 
level of miR-21 expression in LS174T cells downregu-
lated PDCD4 protein expression at post-transcription 
level, and enhanced tumor cell invasion in vitro38 and dis-
tant metastasis in vivo. Our findings showed that LNA-
anti-miR-21 reduced cell migration and cluster-forming 
ability of LS174T cells. In particular, we successfully 
Figure 5. Inhibition of miR-21 reduced liver metastasis in CAM model. (a) Scheme of the spontaneous metastasis chick model. (b) 
The inhibition of spontaneous metastasis cells in a chick model treated with the LNA-anti-miR group compared with the untreated 
and scrambled LNA–treated cells groups. Cells were grafted in CAM at day 10; tumors and livers were harvested on day 18. MiR-
21 knockdown by LNA-anti-miR-21 reduced metastasis of LS174T cells in the chick embryo spontaneous metastasis model.
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Figure 6. Validation of Alu PCR assays. (a) Human genomic DNA was extracted from LS174T cells, which had been serially 
diluted by 10-fold (lines 1, 22 ng/100,000 cells; lines 2, 2.2 ng/10,000 cells; lines 3, 0.22 ng/1000 cells; lines 4, 0.022 ng/100 cells; 
and lines 5, 0.00022 ng/10 cells), and then, Alu PCR was performed to detect human-specific Alu repeats in the liver lobes of chick 
embryo. The Alu standard curve was generated with the concentration of total DNA/numbers of tumor cells and threshold cycle 
of the 10-fold serially diluted human genomic DNA samples. These results were used to estimate the number of LS174T cells in 
liver by comparison with a standard curve. (b) The livers from each chick embryo were harvested 8 days later and subjected to 
quantitative real-time Alu PCR analysis. chGAPDH was used as an internal control. The ∆∆CT method was used for data analysis, and 
the untreated group was considered as a reference for each time point. Data were mean ± SD of three independent experiments 
(**p < 0.01). (c) Number of tumor cells metastasized to the liver was counted. Data were mean ± SD of three independent 
experiments (**p < 0.01). (d) Concentration of human genomic DNA metastasized to the liver was estimated. Data were mean ± 2SE 
of three independent experiments in the graph (**p < 0.01).
developed a CAM model using LS174T CRC cells. Also, 
the average number of tumor cells in the liver was sig-
nificantly reduced in the eggs treated with LNA-anti-miR 
compared with the scrambled LNA and untreated cells. It 
seems that this performance is due to the effect of inhibit-
ing the activity of matrix-metalloproteinase and inhibi-
tion of u-PAR, which is in agreement with several 
previous studies.35,38,46–51
Conclusion
Our study confirms that miR-21 triggers carcinogenic 
progression. Nowadays, miRNA-based therapeutic drug 
has moved to clinical trials, and it is possible to become 
a potential therapeutic target for cancers. In aggregate, 
our data illustrated that the inhibition of oncogenic role 
of miR-21 impairs the metastatic characteristic of colon 
adenocarcinoma cells, supporting further investigation 
on the therapeutic potential of LNA-anti-miR-21 as a 
new option for treatment of CRC.
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